Skip to content

GLP-1 calculator

BMI for Wegovy, Zepbound and Mounjaro: Calculator

Enter your height and weight to get your BMI, then see whether it meets the criteria written in the US labels for Wegovy and Zepbound, the UK licence for Mounjaro and Wegovy, and the stricter NHS rules in England.

Updated

Height
Weight

For adults 18 and over. Teens are covered further down the page.

Weight-related conditions you've been diagnosed with

Tick any that apply. Leave them all empty if none do.

Only changes the NHS lines, which NICE lowers by 2.5 for these backgrounds.

Quick answer

In the US, Wegovy and Zepbound are approved for adults with obesity (a BMI of 30 or more) or overweight (27 to 29.9) plus at least one weight-related condition, such as high blood pressure. The UK licence for Mounjaro and Wegovy uses the same lines. The NHS in England asks for more: a BMI of 35 or more for Mounjaro, offered first at 40 with four conditions. Ozempic isn't approved for weight loss.

The weight at each BMI line, by height

HeightBMI 27BMI 30BMI 35BMI 40
4 ft 10 in (147 cm)129 lb59 kg144 lb66 kg168 lb76 kg192 lb87 kg
5 ft 0 in (152 cm)138 lb63 kg154 lb70 kg179 lb82 kg205 lb93 kg
5 ft 2 in (157 cm)148 lb67 kg164 lb75 kg192 lb87 kg219 lb100 kg
5 ft 4 in (163 cm)158 lb72 kg175 lb80 kg204 lb93 kg233 lb106 kg
5 ft 6 in (168 cm)167 lb76 kg186 lb85 kg217 lb99 kg248 lb113 kg
5 ft 8 in (173 cm)178 lb81 kg197 lb90 kg230 lb105 kg263 lb120 kg
5 ft 10 in (178 cm)188 lb86 kg209 lb95 kg244 lb111 kg279 lb127 kg
6 ft 0 in (183 cm)199 lb91 kg221 lb101 kg258 lb117 kg295 lb134 kg
6 ft 2 in (188 cm)210 lb96 kg234 lb106 kg273 lb124 kg312 lb142 kg
6 ft 4 in (193 cm)222 lb101 kg247 lb112 kg288 lb131 kg329 lb149 kg
6 ft 6 in (198 cm)234 lb106 kg260 lb118 kg303 lb138 kg346 lb157 kg

BMI 27 and 30 are the lines in the US labels and the UK licence; 35 and 40 are NHS England's. NICE lowers the NHS lines by 2.5 for South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds.

Watch your BMI change with every weigh-in

Mingo works out your BMI from your height and each weight you log, with the same formula and categories as this calculator, and the PDF report you can share with your doctor shows it from your first log to today.

Rated 4.7 out of 5 on the App Store · 1,579 ratings

How your BMI is worked out

BMI is your weight in kilograms divided by the square of your height in meters. Someone 1.68 m tall (5 ft 6 in) who weighs 86 kg (190 lb) has a BMI of 86 ÷ (1.68 × 1.68) = 30.5. The calculator converts pounds, stone and feet for you, and rounds to one decimal, the number a prescriber would write down. It uses the same formula and the same category lines as the Mingo app.

BMI Adult category (CDC)
Under 18.5 Underweight
18.5 to 24.9 Healthy weight
25 to 29.9 Overweight
30 to 34.9 Obesity, class 1
35 to 39.9 Obesity, class 2
40 or more Obesity, class 3

These categories are for adults 20 and over (CDC). For children and teens, BMI is read as a percentile for age and sex instead.

Label wording versus the numbers you see online

Most pages say the Wegovy label requires “a BMI of 30, or 27 with a condition”. The current US labels don’t print those numbers in their indication. They say Wegovy and Zepbound are for adults “with obesity” or “with overweight in the presence of at least one weight-related comorbid condition”. The numbers come from the trials described further down the same labels, which enrolled people with a BMI of 30 or more, or 27 to under 30 plus a condition such as dyslipidemia, high blood pressure, sleep apnea or cardiovascular disease (Wegovy and Zepbound prescribing information). The UK licences do print them, as a starting BMI (Mounjaro and Wegovy SmPCs).

Medicine Approved for weight? Who, in the label’s words BMI lines used
Wegovy injection (US) Yes Adults with obesity, or overweight with 1+ weight-related condition; ages 12+ with obesity 30, or 27 to 29.9 with a condition (trials); 95th percentile for teens
Wegovy tablets (US) Yes Adults with obesity, or overweight with 1+ weight-related condition 30, or 27 to 29.9 with a condition (trials)
Zepbound (US) Yes Adults with obesity, or overweight with 1+ weight-related condition; also sleep apnea in adults with obesity 30, or 27 to 29.9 with a condition (trials)
Ozempic (US) No Adults with type 2 diabetes None
Mounjaro (US) No Adults and children 10+ with type 2 diabetes None
Mounjaro (UK licence) Yes Adults, starting BMI 30+, or 27 to under 30 with a condition 30, or 27 to 29.9 with a condition
Wegovy (UK licence) Yes Adults, starting BMI 30+, or 27 to under 30 with a condition; ages 12+ with obesity and over 60 kg 30, or 27 to 29.9 with a condition

So the lines are the same on both sides of the Atlantic for adults. What differs is who pays, and that’s where the NHS comes in.

Ozempic and the US Mounjaro label cover type 2 diabetes, not weight (Ozempic and Mounjaro prescribing information). Their weight-loss counterparts are Wegovy (semaglutide) and Zepbound (tirzepatide); the Ozempic vs Wegovy comparison goes through the differences.

The NHS in England sets a higher bar

Private prescribers in the UK work from the licence above. The NHS in England follows NICE, which recommends both medicines for fewer people:

  • Mounjaro (tirzepatide): adults with a starting BMI of at least 35 and at least one weight-related condition (NICE TA1026). NHS England is bringing it in by groups, counting five conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes.
  • Wegovy (semaglutide): only through a specialist weight management service, for up to 2 years, in adults with at least one weight-related condition and a BMI of 35 or more, or 30 to 34.9 if they also meet the referral criteria for those services (NICE TA875).
Mounjaro on the NHS in England BMI Conditions (of the 5) When, per NICE
Group 1 40 or more 4 or more Now
Group 2 35 to 39.9 4 or more From around June 2026
Group 3 40 or more 3 From around March 2027

For people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean background, NICE lowers every one of these lines, usually by 2.5: 40 becomes 37.5 and 35 becomes 32.5. Tick that box in the calculator and it applies the lower lines to the NHS results only, since the licences don’t adjust. How fast each group is reached also depends on your local NHS area.

Scotland, Wales and Northern Ireland decide separately. In Scotland, the Scottish Medicines Consortium accepted Mounjaro for adults with a BMI of 30 or more and at least one weight-related condition (SMC2653).

Teenagers

Adult BMI lines don’t apply under 18, which is why the calculator is for adults. The Wegovy injection is approved from age 12 for obesity, which its trial defined as a BMI at or above the 95th percentile for age and sex; the UK licence adds a body weight above 60 kg and lists the 95th-percentile BMI for each half-year of age (for example 26.0 for a 14-year-old boy and 27.2 for a 14-year-old girl). To find a teen’s percentile, use the CDC Child and Teen BMI Calculator. Zepbound, Wegovy tablets and the UK Mounjaro weight licence are for adults only.

What a BMI check doesn’t cover

Meeting the BMI criteria is where a prescriber starts, not the decision. BMI is a screening number: it can’t tell muscle from fat or show where you carry weight, which is why the CDC says it should be considered with other factors. The labels also list people who shouldn’t take these medicines at any BMI, including anyone with a personal or family history of medullary thyroid cancer or with multiple endocrine neoplasia syndrome type 2 (MEN 2), and anyone who has had a serious allergic reaction to the medicine.

If your BMI meets the criteria, the next questions are about dose and results: the Wegovy dosage chart and Zepbound dosage chart show the steps, and the GLP-1 weight loss calculator shows what the trials found at each dose.

Following your BMI once you start

Your starting BMI is the one the criteria use, and NICE and the UK Wegovy licence ask for a review if less than 5% of your starting weight is gone after 6 months. Logging your weight regularly makes both easy to answer: Mingo works out your BMI from your height and every weight you log, with the formula and categories this page uses, and keeps your starting point for the report you can share with your prescriber.

Frequently asked questions

What BMI do you need for Wegovy?

For adults, the label covers obesity, which its trials defined as a BMI of 30 or more, or overweight (27 to 29.9) with at least one weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. The Wegovy injection is also approved from age 12 for obesity, measured as a BMI at or above the 95th percentile for age and sex.

What BMI do you need for Mounjaro in the UK?

The UK licence covers adults with a starting BMI of 30 or more, or 27 to 29.9 with a weight-related condition, and private prescribers work from that. On the NHS in England, NICE sets a BMI of at least 35 with a weight-related condition, and NHS England is bringing it in by groups, starting with a BMI of 40 or more and 4 of 5 listed conditions.

What BMI do you need for Ozempic?

Ozempic has no BMI requirement because it isn't approved for weight loss: its US label covers blood sugar control and heart and kidney risk in adults with type 2 diabetes. Wegovy is the same medicine, semaglutide, approved for weight. Any Ozempic prescription for weight alone is off-label.

What counts as a weight-related condition?

The trials behind the US labels gave examples like high blood pressure, high cholesterol (dyslipidemia), obstructive sleep apnea, cardiovascular disease and type 2 diabetes. The UK Mounjaro licence adds prediabetes. NHS England counts five for Mounjaro: high blood pressure, dyslipidaemia, sleep apnoea, cardiovascular disease and type 2 diabetes.

Is the BMI line lower for some ethnic groups?

On the NHS, yes. NICE lowers its thresholds, usually by 2.5, for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean background, so 35 becomes 32.5 and 40 becomes 37.5. The US labels and the UK licence don't adjust their lines.

Can teenagers take Wegovy or Mounjaro for weight loss?

The Wegovy injection is approved from age 12 for obesity, defined by BMI percentile for age and sex rather than adult BMI; in the UK the licence also needs a body weight above 60 kg. Zepbound, Wegovy tablets and the UK Mounjaro licence for weight are for adults only.

If my BMI drops below 30 on treatment, do I have to stop?

The criteria are about the BMI you start from: the UK licence says 'initial BMI'. Whether to keep going is your prescriber's call; NICE and the UK Wegovy licence say to review treatment if you haven't lost at least 5% of your starting weight after 6 months.

Does my insurance use the same BMI lines?

Not necessarily. The label sets who the medicine is approved for; your plan decides what it pays for and can add its own requirements, such as prior authorization. Check your plan's coverage rules before you're prescribed.

Sources

Updated .

  1. Wegovy injection and tablets prescribing information, revised 6/2026, sections 1, 4 and 14 (DailyMed)
  2. Zepbound prescribing information, revised 8/2026, sections 1, 4 and 14 (DailyMed)
  3. Ozempic prescribing information, section 1 (DailyMed)
  4. Mounjaro prescribing information, section 1 (DailyMed)
  5. Mounjaro KwikPen summary of product characteristics (UK), revised 29 August 2026, section 4.1 (emc)
  6. Wegovy FlexTouch summary of product characteristics (UK), revised 9/2026, section 4.1 (emc)
  7. NICE TA1026: Tirzepatide for managing overweight and obesity (updated 1 September 2025)
  8. NICE TA875: Semaglutide for managing overweight and obesity (updated 4 September 2023)
  9. Scottish Medicines Consortium: tirzepatide (Mounjaro) SMC2653 (10 June 2024)
  10. CDC: Adult BMI categories
  11. CDC: Child and Teen BMI Calculator

GLP-1 calculators and dose charts